Mirum Pharmaceuticals (MIRM) said late Tuesday it plans to offer $600 million of senior notes due 2032.
The company will grant the initial buyers a 13-day overallotment option to buy up to an additional $90 million of the notes, according to a statement.
Net proceeds will be used to cover note exchange transactions and for general corporate purposes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.